心肌靶向载L-精氨酸纳米颗粒对脓毒症心肌损伤的保护作用
研究制备心肌细胞特异性肽修饰、负载L-精氨酸的介孔硅纳米颗粒(PCM-MSN@LA),表征粒径约180 nm、Zeta电位约-21 mV,L-精氨酸修饰量与释放率分别为12.3%和24.3%,并证实其心肌靶向能力。细胞实验中,与单用LPS相比,PCM-MSN@LA/LPS组细胞活力更高、活性氧更低、凋亡更少,内皮型与诱导型一氧化氮合酶表达升高,且效应优于非靶向MSN@LA/LPS组。小鼠实验中,PCM-MSN@LA/LPS组较LPS组左室射血分数与左室短轴缩短率更高、白细胞介素1、白细胞介素6与肿瘤坏死因子α mRNA表达更低,24小时存活数4只 vs 1只(P=0.03)。作者结论认为该靶向纳米颗粒可减轻脓毒症心肌损伤,实现靶向治疗。
要点
- 小鼠脓毒症模型中,尾静脉注射0.5 mg/kg PCM-MSN@LA较LPS组提高左室射血分数(0.456±0.019 vs 0.337±0.017)与左室短轴缩短率(21.97±1.78% vs 15.53±1.67%),均P<0.05。
- PCM-MSN@LA/LPS组24小时存活数为4只,LPS组为1只(P=0.03);非靶向MSN@LA/LPS组为2只,与LPS组比较P=0.36,未达统计学显著。
- 细胞实验中PCM-MSN@LA/LPS组较MSN@LA/LPS组细胞活力更高(A值0.51±0.08 vs 0.41±0.03)、活性氧更低(28 450±1 941 vs 35 628±2 551),均P<0.05。
- PCM-MSN@LA/LPS组较LPS组降低白细胞介素1、白细胞介素6与肿瘤坏死因子α mRNA表达(IL-1:169.22±8.95 vs 189.79±6.79,IL-6:19.90±1.60 vs 23.74±1.45,TNF-α:8.21±0.81 vs 11.00±1.48,均P<0.05)。
- 非靶向MSN@LA/LPS组与LPS组各指标无显著差异,提示心肌靶向修饰是效应增强的关键。
适用人群与场景
- 实验一:SD新生大鼠心肌细胞,经5 mg/L脂多糖刺激16小时建立脓毒症心肌细胞损伤模型。
- 实验二:64只健康雄性C57BL/6小鼠,随机分为假手术组、LPS组、MSN@LA/LPS组与PCM-MSN@LA/LPS组,每组16只;LPS组腹腔注射50 mg/kg脂多糖。
处置流程与药物剂量
- 细胞实验:LPS组以5 mg/L脂多糖刺激16小时;MSN@LA/LPS组与PCM-MSN@LA/LPS组以5 mg/L脂多糖加25 mg/L含L-精氨酸纳米颗粒(分别为MSN@LA与PCM-MSN@LA)处理16小时。
- 小鼠实验:腹腔注射50 mg/kg脂多糖后立即经尾静脉注射0.5 mg/kg MSN@LA或PCM-MSN@LA。
研究设计与关键结果
- 研究类型:纳米颗粒制备与表征加细胞实验和小鼠实验;PCM-MSN@LA呈球形,粒径约180 nm,Zeta电位约-21 mV,L-精氨酸修饰量12.3%、释放率24.3%,细胞吞噬实验显示其具有心肌细胞与心肌组织靶向能力。
- 细胞实验:脂多糖刺激后心肌细胞活力下降,活性氧生成、凋亡及内皮型与诱导型一氧化氮合酶蛋白表达升高;与LPS组相比,MSN@LA/LPS组与PCM-MSN@LA/LPS组细胞活力更高、活性氧与凋亡减少、两种一氧化氮合酶表达升高。
- 细胞实验组间比较:PCM-MSN@LA/LPS组 vs MSN@LA/LPS组,细胞活力(A值)0.51±0.08 vs 0.41±0.03,活性氧(相对荧光强度)28 450±1 941 vs 35 628±2 551,TUNEL阳性细胞/总细胞0.27±0.03 vs 0.35±0.04,eNOS/β-Tubulin 1.467±0.046 vs 1.201±0.131,iNOS/β-Tubulin 1.700±0.033 vs 1.577±0.068,均P<0.05。
- 小鼠24小时存活数:MSN@LA/LPS组2只、PCM-MSN@LA/LPS组4只 vs LPS组1只,P值分别为0.36和0.03。
- 小鼠心功能与炎症指标:与LPS组相比,PCM-MSN@LA/LPS组左室射血分数更高(0.456±0.019 vs 0.337±0.017)、左室短轴缩短率更高(21.97±1.78% vs 15.53±1.67%),IL-1 mRNA(169.22±8.95 vs 189.79±6.79)、IL-6 mRNA(19.90±1.60 vs 23.74±1.45)、TNF-α mRNA(8.21±0.81 vs 11.00±1.48)表达更低,均P<0.05。
- MSN@LA/LPS组与LPS组各指标无显著差异。
证据类型、等级与局限
- 证据类型:基础研究(纳米颗粒制备、细胞实验与小鼠在体实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,具有心肌靶向特征的PCM-MSN@LA可显著提高心肌细胞活性、下调炎症因子表达与活性氧生成、减轻脓毒症心功能不全,实现脓毒症心肌损伤的靶向治疗。
- 上述结果来自细胞与小鼠实验,原文未据此给出急诊或ICU临床应用推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To prepare primary cardiomyocyte (PCM) specific peptide-conjugated mesoporous silicon nanoparticles (MSN) with L-arginine (LA) as a core (PCM-MSN@LA), and evaluate its specific protective effect on septic myocardium.
METHODS: PCM-MSN@LA was prepared by condensation reaction, the characterization of PCM-MSN@LA, the amount of LA modification and release was detected, and the phagocytosis of PCM-MSN@LA and its affinity to myocardial tissue was observed. (1) Experiment one: SD neonatal rat cardiomyocytes were divided into control group (Con group), lipopolysaccharide (LPS) group, MSN@LA/LPS group and PCM-MSN@LA/LPS group. The LPS group was stimulated with 5 mg/L LPS for 16 hours, while the MSN@LA/LPS group and PCM-MSN@LA/LPS group were treated with 5 mg/L LPS and 25 mg/L LA-containing nanoparticles (MSN@LA and PCM-MSN@LA) for 16 hours. Cell viability and reactive oxygen species (ROS) production levels were detected. Apoptosis was observed via terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method (TUNEL). Western Blot was used to detect the changes in endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) proteins. (2) Experiment two: 64 healthy male C57BL/6 mice were divided into Sham group, LPS group, MSN@LA/LPS group and PCM-MSN@LA/LPS group by random number table method, 16 mice in each group. LPS group were injected 50 mg/kg LPS intraperitoneally. MSN@LA/LPS group and PCM-MSN@LA/LPS group were injected with 0.5 mg/kg MSN@LA and PCM-MSN@LA via tail vein immediately after intraperitoneal injection of LPS. Eight animals in each group were used to observe the 24-hour survival rate, and the other 8 mice were used to detect cardiac function by echocardiography at 12 hours after operation; mRNA expressions of interleukin (IL-1, IL-6) and tumor necrosis factor-α (TNF-α) were measured by real-time fluorescent quantitative polymerase chain reaction (RT-qPCR).
RESULTS: PCM-MSN@LA was spherical, with particle size of about 180 nm, Zeta potential of about -21 mV, with LA loaded. The amount of LA modification and release rate were 12.3% and 24.3%, respectively. Cell phagocytosis experiments showed that PCM-MSN@LA had the targeting ability of cardiomyocytes and myocardial tissue. Experiment one: after LPS stimulation of myocardial cells, cell viability decreased, while ROS generation, apoptosis, eNOS and iNOS protein expressions increased. Compared with LPS group, MSN@LA/LPS group and PCM-MSN@LA/LPS group had higher cell viability, reduced ROS levels and apoptosis, increased expressions of eNOS and iNOS. PCM-MSN@LA/LPS group changed the above effect further than MSN@LA/LPS group [cell viability (A value): 0.51±0.08 vs. 0.41±0.03, ROS (relative fluorescence intensity): 28 450±1 941 vs. 35 628±2 551, TUNEL positive cells/total cells: 0.27±0.03 vs. 0.35±0.04, eNOS/β-Tubulin: 1.467±0.046 vs. 1.201±0.131, iNOS/β-Tubulin: 1.700±0.033 vs. 1.577±0.068, all P < 0.05]. Experiment two: the number of 24-hour survive in MSN@LA/LPS group and PCM-MSN@LA/LPS group were higher than LPS group (number: 2, 4 vs. 1, P values were 0.36 and 0.03 respectively). Compared with Sham group, the cardiac function of LPS group was significantly inhibited and the mRNA expression of inflammatory factors increased. The PCM-MSN@LA/LPS group had higher left ventricular ejection fraction (LVEF) and left ventricular short-axis shortening rate (LVFS) than LPS group, and lower mRNA expressions of IL-1, IL-6, and TNF-α mRNA [LVEF: 0.456±0.019 vs. 0.337±0.017, LVFS: (21.97±1.78)% vs. (15.53±1.67)%, IL-1 mRNA (2-ΔΔCT): 169.22±8.95 vs. 189.79±6.79, IL-6 mRNA (2-ΔΔCT): 19.90±1.60 vs. 23.74±1.45, TNF-α mRNA (2-ΔΔCT): 8.21±0.81 vs. 11.00±1.48, all P < 0.05]. There was no significant difference in each index between the MSN@LA/LPS group and LPS group.
CONCLUSIONS: PCM-MSN@LA with myocardial targeting characteristic significantly increased the activity of myocardial cells, down-regulated the expression of inflammatory factors and the production of ROS, alleviated cardiac insufficiency in sepsis, and achieved the targeted treatment of myocardial injury in sepsis.
参考来源
- Peng Z, Zhang M, Ouyang M, et al. [Protective effects of myocardium-targeted nanoparticles loaded L-arginineon on sepsis-induced myocardial injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32912409. doi:10.3760/cma.j.cn121430-20200217-00168
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。